^
    Back
    Association details:
    Biomarker:PALB2 mutation
    Cancer:Pancreatic Adenocarcinoma
    Drug:cisplatin (DNA synthesis inhibitor) +
    gemcitabine (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Pancreatic Adenocarcinoma: Preferred Regimens…Only for known BRCA1/2 or PALB2 mutations…Gemcitabine + cisplatin
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Radiation Therapy (RT) and Chemotherapy for the Treatment of Pancreatic Cancer With Homologous Recombination Deficiency That Has Spread to the Liver

    Excerpt:
    ...- Germline or biallelic somatic pathogenic mutations in the core HR genes including BRCA1, BRCA2, PALB2 and ATM genes are required for dose escalating cohort....
    Trial ID:
    NCT05182112